CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Generics  /  Generic Formulations

GENERIC FORMULATIONS

Overview

Providing a continuity of supply to complex generic medication

At Biocon, patients are our priority. Our secure integrated supply chain along with a stellar compliance history safeguards their treatments with access to a continuous supply of medicines. By developing a robust pipeline of differentiated generic finished dosages for global markets, we fulfil their demand for quality and affordable healthcare.

Healthcare today

For severe chronic and lifestyle diseases, medication consumption is virtually lifelong and creates a demand for affordable variants, which generic drugs can provide.

The demand for pharmaceuticals is being driven by enhanced life expectancy, rising affordability and improved standard of living. These factors, together with sedentary lifestyles, changing dietary patterns and demanding work schedules are responsible for an increasing prevalence of hypertension, diabetes, dyslipidaemia, metabolic syndrome and obesity. For severe chronic and lifestyle diseases, medication consumption is virtually lifelong and creates a demand for affordable variants, which generic drugs can provide. At Biocon Generics, we are developing a portfolio of complex generic formulations to create reliable and affordable access to these medicines.

BIOCON GENERIC FORMULATIONS

The strength of our generic formulations business is powered by our portfolio of complex and differentiated APIs. Forward integration into dosage forms fulfils our commitment to provide continuity of supply of affordable quality medicines to patients across geographies. At Biocon, we have commenced multiple programs to build a robust pipeline of technology-intensive molecules for global markets. Biocon has successfully commercialised a few products under its own label in the US and is gradually expanding its reach to other geographies as well.

Siddharth Mittal
KEY MANAGEMENT TEAM
PRODUCTS
PRESS RELEASES
CORPORATE GOVERNANCE
R&D
WORKING WITH US
Share